Difference between revisions of "Sancak Y, et al. Mol. Cell (2007) cited as Ref 357 in DOI: 10.1038/s41392-020-0110-5 (Q9620)"
Jump to navigation
Jump to search
(Created claim: Publication Date (P100): 2007, #quickstatements; #temporary_batch_1590002823654) |
(Created claim: Page(s) (P105): 903-915, #quickstatements; #temporary_batch_1590074839150) |
||
| (3 intermediate revisions by the same user not shown) | |||
| Property / Published In Name String | |||
| + | Mol. Cell | ||
| Property / Published In Name String: Mol. Cell / rank | |||
| + | Normal rank | ||
| Property / Volume | |||
| + | 25 | ||
| Property / Volume: 25 / rank | |||
| + | Normal rank | ||
| Property / title | |||
| + | PRAS40 is an insulin-regulated inhibitor of the mTORC1 protein kinase (English) | ||
| Property / title: PRAS40 is an insulin-regulated inhibitor of the mTORC1 protein kinase (English) / rank | |||
| + | Normal rank | ||
| Property / Page(s) | |||
| + | 903-915 | ||
| Property / Page(s): 903-915 / rank | |||
| + | Normal rank | ||
Latest revision as of 15:38, 21 May 2020
Cited in: "Targeting cancer stem cell pathways for cancer therapy" in Signal Transduct Target Ther; 2020 ; 5 8
| Language | Label | Description | Also known as |
|---|---|---|---|
| English |
Sancak Y, et al. Mol. Cell (2007) cited as Ref 357 in DOI: 10.1038/s41392-020-0110-5
|
Cited in: "Targeting cancer stem cell pathways for cancer therapy" in Signal Transduct Target Ther; 2020 ; 5 8
|
Statements
Sancak Y
0 references
2007
0 references
Mol. Cell
0 references
25
0 references
PRAS40 is an insulin-regulated inhibitor of the mTORC1 protein kinase (English)
0 references
903-915
0 references
